Xenetic Biosciences, Inc.

NasdaqCM:XBIO

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 5.98 M

Share Price

USD 3.88

Avg Daily Volume

8,263

Change (1 day)

23.18%

Change (1 year)

1.31%

Change (YTD)

-2.76%

Xenetic Biosciences, Inc. Enterprise Value to EBITDA (EV/EBITDA) on June 25, 2025

Xenetic Biosciences, Inc. Enterprise Value to EBITDA (EV/EBITDA) is NA on June 25, 2025. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Xenetic Biosciences, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 25, 2025, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Xenetic Biosciences, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 25, 2025, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Xenetic Biosciences, Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NasdaqCM: XBIO

Xenetic Biosciences, Inc.

CEO	Mr. James F. Parslow
IPO Date	June 30, 2016
Location	United States
Headquarters	40 Speen Street
Employees	2
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.